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Abstract 
 
Background: Cancer of unknown primary origin (CUP) is defined by the presence of 
pathologically identified metastatic disease without clinical or radiological evidence of a primary 
tumour. Our objective was to identify incident cases of CUP in Ontario, Canada, and determine 
the influence of histology and sites of metastases on overall survival (OS). 
Material and Methods: We used the Ontario Cancer Registry (OCR) and the Same-Day 
Surgery and Discharge Abstract Database (SDS/DAD) to identify patients diagnosed with CUP 
in Ontario between January 1, 2000, and December 31, 2005. Patient diagnostic information, 
including histology and survival data, was obtained from the OCR. We cross-validated CUP 
diagnosis and obtained additional information about metastasis through data linkage with the 
SDS/DAD database. OS was assessed using Cox regression models adjusting for histology and 
sites of metastases.  
Results: We identified 3,564 patients diagnosed with CUP. Patients without histologically 
confirmed disease (n=1,821) had a one-year OS of 10.9%, whereas patients with confirmed 
histology (n=1,743) had a one-year OS of 15.6%. The most common metastatic sites were in the 
respiratory or digestive systems (n=1,603), and the most common histology was adenocarcinoma 
(n=939). Three-year survival rates were 3.5%, 5.3%, 41.6% and 3.6% among adenocarcinoma, 
unspecified carcinoma, squamous cell carcinoma and undifferentiated histology, respectively. 
Three-year survival rates were 40%, 2.4%, 8.0% and 4.6% among patients with metastases 
localized to lymph nodes, the respiratory or digestive systems, other specified sites, and 
unspecified sites, respectively. 
Conclusion: CUP patients in Ontario have a poor prognosis. Some subgroups may have better 
survival rates, such as patients with metastases localized to lymph nodes and patients with 
squamous cell histology. 
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Background 
 The primary objective for physicians treating patients presenting with a metastatic cancer 
is to identify the tumour’s site of origin. The typical diagnostic work-up includes a detailed 
analysis of medical history, complete physical examination, full blood count and biochemical 
analysis, urinalysis and stool occult blood tests, histopathological review of the metastatic 
tumour biopsy and computed tomography (CT) scan of the chest, abdomen and pelvis [1]. If the 
primary tumour remains occult, examining metastatic tumour samples with additional 
immunohistochemical (IHC) staining becomes crucial in establishing a potential originating 
tissue as well as for directing further examination [2]. Additionally, tests such as mammography, 
upper and lower gastro-intestinal endoscopy, magnetic resonance imaging (MRI) and positron 
emission tomography (PET) may be considered. If the site of the primary tumour remains 
unidentified after additional diagnostic work-up, then the patient is considered to have cancer of 
unknown primary site or origin (CUP). The overall prognosis of CUP patients is poor, with an 
estimated three- to 10-month median survival [1]. While CUP accounts for approximately 3% to 
5% of all incident cancers, it ranks among the top five causes of cancer deaths worldwide [3, 4]. 
 Currently, little is known about the biology of CUP [3]. Epidemiological analyses of 
CUP cases have identified clinicopathological features, including sex, sites of the metastatic 
tumour and histopathology, that predict a favourable prognosis [4-6]. About 20% of CUP 
patients belong to favourable subsets and respond well after receiving site-specific therapies [1, 
3, 7]. However, the majority of CUP patients do not fit into a favourable subset and present with 
metastatic cancer of major organs and multiple metastases [8]. While median survival in the 
unfavourable subgroup is under one year, prolonged survival in the favourable subgroup can 
extend beyond 13 years [7, 8]. 
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 In this study, we identify a cohort of CUP patients in Ontario, Canada, using provincial 
registries and administrative databases. We describe patient characteristics and examine overall 
survival using subgroups defined by histology and metastatic site. Similar studies have been 
conducted in Europe, but we are not aware of any published data on CUP survival in Canada [9-
12].  
Materials and Methods 
Data Sources 
 We used the Ontario Cancer Data Linkage project “cd-link” to obtain data from 
population-based administrative databases for Canada’s largest province. The cd-link project is a 
data release mechanism in which patient-level data relevant to cancer research are linked at the 
Institute for Clinical Evaluative Sciences using encrypted health card numbers, de-identified, 
and, with the protections of a comprehensive Data Use Agreement (DUA), are provided to 
investigators at academic institutions in Ontario. Through the cd-link project, we gained access 
to the Ontario Cancer Registry (OCR) database and the Canadian Institute for Health 
Information (CIHI) Same-Day Surgery and Discharge Abstract Database (SDS/DAD). Ethics 
approval was obtained prior to accessing these databases. 
Maintained by Cancer Care Ontario (CCO), the OCR is an electronic database  that tracks 
all incident cases of cancers and associated mortality in Ontario. The OCR contains patient 
information that is compiled from the following sources: hospital pathology reports with a cancer 
diagnosis, patient records from CCO, electronic death records from the Registrar General of 
Ontario and hospitalization records documenting a cancer diagnosis from SDS/DAD (CIHI). 
Patient data from these sources are linked using probabilistic linkage, and each patient is 
assigned a unique identifier. For each patient, the OCR contains patient information, including 
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their regional cancer centre registration date, whether an autopsy was completed, histology of 
biopsy, cause of death, institution of diagnosis, number of primary tumours and their first 
treatment date. The most up-to-date patient cancer diagnosis is recorded in the OCR database 
using the International Classification of Diseases 9th (ICD-9) before 2002 and ICD 10th (ICD-
10) afterwards. The data quality of the OCR has been examined previously and was found to be 
highly accurate [13]. 
  The SDS/DAD database contains patient-level data for acute, rehabilitation, chronic and 
day-surgery institutions in Ontario. Each observation in this database contains information about 
one hospital stay (DAD) or one same-day surgery stay (SDS). This database contains 
information regarding sex, date of birth, up to 25 diagnoses per hospitalization, procedures 
undertaken, length of stay and several variables indicating resource consumption.  
 Identification of CUP Population 
We identified patients using the OCR and the SDS/DAD database. We defined CUP 
cases as any Ontario resident who was registered by the OCR during the period from January 1, 
2000, to December 31, 2005, with one or more of the following diagnosis codes: cancer of 
unknown primary with metastatic sites localized to lymph nodes (ICD-9:196/ICD-10:C77), the 
respiratory or digestive systems (ICD-9:197/ICD-10:C78), other specified sites (ICD-9:198/ICD-
10:C79), or without specification of metastatic site (ICD-9:199/ICD-10:C80). We used the 
SDS/DAD database to verify CUP diagnosis and inclusion in the cohort. We included patients 
where there was evidence in the SDS/DAD database of metastatic disease and CUP diagnosis 
from two months before until two months after the initial diagnosis. We excluded patients whose 
CUP diagnosis was changed to any other site later in the course of the disease and those who had 
a previous known primary cancer diagnosis (Figure 1). 
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We grouped patients by histology types using the International Classification of Diseases 
for Oncology, 3rd Edition (ICD-O-3) histology codes available from the OCR. The following 
ICD-O-3 codes were utilized: adenocarcinoma (8140-8580), squamous cell carcinoma (8050-
8089), unspecified carcinoma (8010-8049) and undifferentiated (8000-8004). Patients with no 
histologically confirmed disease (i.e., ICD-O-3 9990) were grouped in one category. All 
remaining ICD-O-3 codes were compiled as “other”. We obtained five-year survival data from 
the OCR. 
  Statistical Analysis 
 All statistical analyses were performed using SAS software version 9.3 (SAS Institute, 
Cary, NC, U.S.A). The Kaplan-Meier method was used to generate survival curves, and the 
primary endpoint of this analysis was overall survival (OS). We used the log-rank test to assess 
the difference between survival curves of metastatic site and histology. We obtained hazard 
ratios (HRs) and 95% confidence intervals using Cox regression analyses adjusted for age and 
sex. All statistical tests were two-tailed and were conducted at the 5% significance level. Cell 
sizes of fewer than five patients were not reported, as required by the cd-link Data Usage 
Agreement. 
Results 
Patient and tumour characteristics are summarized in Table 1. During the study period, 
52,619 patients were diagnosed with metastatic cancer, and of those, 3,564 (6.8%) had a final 
diagnosis of CUP. Histological samples provided the most common method for confirming 
diagnosis (43.8%). Confirmation of tumour cell type via histology was missing for 1,821 
(51.1%) of CUP patients. For CUP patients with confirmed histology, metastatic tumours 
localized to the respiratory or digestive systems were most common (42.8%). Over half of all 
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tumours were adenocarcinomas (n=939). There were significant variations in histology by 
tumour location. For example, adenocarcimona was the most common histology for 
respiratory/digestive CUP (67.6%), other specified sites (43.8%) and unspecified sites (51.9%), 
but it only represented 23.4% of nodal CUP. Squamous cell carcinoma was the most common 
histology among nodal CUP (39.4%), but only represented 2.1% of respiratory/digestive CUP, 
10.3% of other specified site CUP, and 5.4% of unspecified site CUP.   
There was no difference in survival by gender (Table 2). Survival was better for younger 
patients, and this trend was consistent across all age groups. Patients lacking histology were 
older, on average, than those with histology (Table 1). Patients without histology were more 
likely to have unspecified site CUP and less likely to have nodal CUP compared to patients with 
confirmed histology. The overall survival of patients with known histology was significantly 
higher than survival among those without histology (Figure 2). 
 The Kaplan-Meier curves of OS are shown in Figure 3. The overall trend is similar 
among respiratory/digestive, other specified sites and unspecified CUP. Nodal CUP patients had 
a significantly higher one-year OS probability of 52.4% (log-rank p<0.0001) compared to all 
other subgroups. Patients with other specified site CUP were the next highest surviving group, 
with a one-year OS probability of 16.6%. 
We stratified OS estimates by histology (Figure 4). Generally, patients with squamous 
cell carcinoma had higher one- and three-year OS within each metastatic site (Table 3). Patients 
with squamous cell carcinoma had a one-year OS probability of 59.5%, compared to the next 
highest one-year OS probability in the adenocarcinoma group at 11.3%. Nodal CUP with 
adenocarcinoma, squamous cell carcinoma or unspecified carcinoma histology had significantly 
better survival compared to similar histology tumours of other sites. In nodal CUP with 
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undifferentiated histology, only unspecified site CUP had significantly worse survival. Nodal 
CUP had significantly better survival among all comparisons for CUP patients without histology.  
 Discussion    
We identified a cohort of CUP patients in Ontario by cross-validating data from the OCR 
and the SDS/DAD database. Our work revealed that CUP patients in Ontario represent a 
significant portion of all metastatic cancers, accounting for approximately 6.8% of the total. We 
analyzed five-year survival as well as one-year hazard ratio (HR) subgrouped by metastatic site 
and histology. We found that survival varied by metastatic site and histology. Patients with nodal 
CUP had better survival than any other CUP metastatic site. Patients with metastases localized to 
either respiratory or digestive regions generally had some of the worst survival outcomes, 
regardless of histology. Among patients with squamous cell carcinoma, those with non-
respiratory/digestive metastases had the highest survival rates.  
The short time window of data collection and the large cohort size constitute the strengths 
of this study and likely translate into consistent diagnosis and treatment during the collection 
period. Our CUP cohort is smaller than those of large, European-based population studies of 
CUP with sample sizes ranging from 18,911 to 57,638 [9, 11, 14]. However, our work 
encompassed a six-year period, whereas these studies included 21 [9] to 47 [11] years of 
observations. As a consequence, our study did not include CUP cases from the 1990s, a period 
that is suggested to have been the peak of CUP incidence from European cancer registries [11, 
14]. Even without those CUP cases, our sample size is comparable, given the collection window. 
Our findings are consistent with previous research. Increased survival in nodal CUP 
patients and patients with squamous cell histology has been described elsewhere [2, 11, 15] as 
well as decrased survival in respiratory/digestive CUP patients [16]. Our work largely 
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corroborates what is currently known about CUP, but it also shows unique traits of this Canadian 
cohort. In a large Swedish cohort, Hemminki et al. found 24% survival after one year (n=7,730), 
whereas we observed a one-year survival of 13.7% (n=349) for unspecified site CUP patients [9]. 
This variation may be attributed to population differences or, more likely, to alternative 
diagnostic or therapeutic guidelines that occurred over the different time frames. If this observed 
difference can be accounted for by diagnostic or post-diagnostic treatment, it will be important to 
try and implement this aspect into the Canadian setting. 
Among patients with squamous cell carcinoma, those with respiratory/digestive as the 
site had the worst survival outcomes. Lung cancer was identified as the main cause of death for 
extranodal squamous cell carcinoma CUP patients in Sweden [17]. Death from digestive cancers 
was also common. This suggests CUP involving respiratory and digestive sites are directly 
linked with patient outcome. Patients with non-respiratory/digestive squamous cell carcinoma 
may have their metastatic sites located such that treatment by radiation or surgery is possible. 
This is especially true for tumours located in the head and neck or inguinal area [18]. These 
favourable subgroups often present in such a way that a potential originating malignancy is 
suggested, directing therapeutic treatment [19]. 
Historically, therapeutic guidelines for CUP patients have recommended the use of 
platinum-based chemotherapy [2, 20, 21]. Although targeted treatments may be available for 
some subgroups of patients, platinum-based chemotherapy is often recommended to accompany 
such treatment [8]. For the majority of CUP patients, a platinum-based doublet regimen is often 
prescribed [22]. A recent systematic review of the unfavourable subset of CUP has raised 
questions about current clinical practice [23]. Phase II trials completed in the past 15 years have 
yielded inconclusive results regarding chemotherapy over best supportive care, and have not 
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clarified the benefit of treatment regimens with platinum-based chemotherapy over non-
platinum-based chemotherapy with single versus doublet or triplet chemotherapy regimens [23]. 
Future analyses describing treatment received by our study cohort is warranted to describe the 
Canadian clinical practice.  
Fifty-one percent of our sample (1,821/3,564) did not have a confirmed histology. Given 
that this group had poor outcomes, with a minority of patients surviving beyond a few months 
(Figure 2), there may be clinical and administrative factors leading to an absence of histology. 
For instance, these patients may not have survived long enough for pathology analyses to be 
conducted. Many of these patients (98%) had operation as their method of confirmation. It is 
possible that for this subgroup, surgery revealed a poor prognosis such that histological tests 
were not ordered. It is also possible that, for some members of this group, CUP diagnosis was 
used by the registry as a temporary diagnosis but was never updated, so that the final record 
shows unconfirmed histology. Two recent population registry studies reported CUP with no 
histological evidence to comprise 30.3% and 58.4% of CUP cases [15, 24]. While this does not 
prove the accuracy of the CUP diagnosis, it does show these patients represent a significant and 
clinically visible subset of the CUP population. 
The lack of certain information known to be relevant for the CUP population represents a 
limitation of this study. The number of metastatic sites is known to be associated with greater 
disease burden [21]. Indeed, one characteristic of the favourable subset of CUP patients is a 
single metastatic site. Additionally, several prognostic scores have been proposed with potential 
factors associated with CUP patient survival. However, the OCR does not capture the number of 
metastatic sites or prognostic markers, such as lactate dehydrogenase (LDH) level, albumin level 
and performance status [23, 25]. Application and validation of a prognostic model in this large 
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CUP patient cohort could have important consequences in current clinical practice. Capturing the 
above data elements in administrative databases would significantly enhance research in this 
area. Treatment intensity in this cohort could prove to be valuable in establishing costs for 
treating patients with CUP and the relationship between survival and therapeutic procedures. 
This link has yet to be clearly demonstrated for CUP populations [23]. 
 This study shows that CUP patients in Canada constitute a relatively large group of the 
metastatic cancer population and that this population is mainly composed of patients in the 
unfavourable CUP subgroup. Important differences in patient survival between this cohort and 
those identified in previous studies suggest a need for further study. Future research efforts 
should continue to explore new diagnostic tools for this population, especially those with 
unfavourable characteristics.  
Acknowledgments: This study was supported by the Canadian Institutes of Health Research. 
SMM, PKR and GSZ are supported by the Canada Research Chairs Program. 
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Table 1. Demographic characteristics of the CUP cohort. 
Patient characteristics Histologically confirmed Missing histology 
 n=1,743 (%) n=1,821 (%) 
Age (average) 69 76 
     <39 31 (1.8) 22 (1.2) 
     40-49 109 (6.3) 47 (2.6) 
     50-59 235 (13.5) 106 (5.8) 
     60-69 399 (22.9) 237 (13.0) 
     70-79 575 (33.0) 589 (32.3) 
     >80 394 (22.6) 820 (45.0) 
Gender 
 
 
     Male 866 (49.7) 847 (46.5) 
Year of diagnosis 
 
 
     2000 280 (16.1) 308 (16.9) 
     2001 289 (16.6) 337 (18.5) 
     2002 289 (16.6) 298 (16.4) 
     2003 307 (17.6) 315 (17.3) 
     2004 295 (16.9) 275 (15.1) 
     2005 283 (16.2) 288 (15.8) 
Site 
  
 
     Nodal CUP (196/C77) 191 (11.0) 42 (2.3) 
     Respiratory/digestive CUP (197/C78) 746 (42.8) 857 (47.1) 
     Other specified site CUP (198/C79) 457 (26.2) 361 (19.8) 
     Unspecified site CUP (199/C80) 349 (20.0) 561 (30.8) 
Histology 
  
 
     Adenocarcinoma  939 (53.9) 0 
     Squamous cell carcinoma 173 (9.9) 0 
     Unspecified carcinoma  475 (27.3) 0 
     Undifferentiated  139 (8.0) 0 
     Other* 17 (1.0) 0 
     No histological evidence 0 1821 (100) 
Diagnostic conformation method 
 
 
     Histology 1075 (61.7) 0 
     Cytology 341 (19.6) 0 
     Operation 194 (11.1) 1787 (98.1) 
     X-Ray 117 (6.7) 0 
     Unknown or Other 10 (0.6) 34 (1.9) 
     Judgement or autopsy 6 (0.4) 0 
*Includes sarcoma, lymphoma, other hematologic, melanoma and other specified carcinoma.  
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Table 2. One-year hazard ratio (HR) by gender and age group.
  
n HR P-value 
Gender 
   
 
Male 867 1.06 0.2850 
 
Female 876 1.00 Ref 
Age at diagnosis 
   
 
<39 31 0.50 0.0010 
 
40-49 109 0.55 <.0001 
 
50-59 235 0.66 <.0001 
 
60-69 399 0.78 0.0007 
 
70-79 575 0.86 0.0270 
 
>80 394 1.00 Ref 
Ref = Reference group used for hazard ratio calculation 
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Table 3. One-year (1 y), three-year (3 y) survival (%), median overall survival (OS, months) and one-year adjusted hazard ratios (HR) 
stratified by metastatic site and histology (n=1743) 
 Nodal CUP 
(196/C77) 
 Respiratory/digestive CUP 
(197/C78) 
 Other specified sites CUP 
(198/C79) 
 Unspecified site CUP 
(199/C80) 
 Total 
     
 OS 1 y 3 y HR  OS 1 y 3 y HR P-value  OS 1 y 3 y HR P-value  OS 1 y 3 y HR P-value  OS 1 y 3 y 
Adenocarcinoma  
 
 
6.0 35.7 13 1.00  1.4 7.9 3 2.36 <.0001  2.6 11.5 4 1.92 0.0005  1.7 13.7 5 2.10 <.0001  1.8 11.3 3.5 
Squamous cell 
carcinoma 
 
60.0 77.7 59 1.00  2.9 0 0 10.01 <.0001  11.3 51 26.5 2.37 0.0014  12.5 52.6 31.6 2.98 0.0076  20.4 59.5 41.6 
Unspecified 
carcinoma  
 
3.3 33.3 31 1.00  0.8 5.2 NRǂ 2.34 <.0001  2.3 13.5 5.1 1.50 0.0539  0.9 3.7 NRǂ 2.49 <.0001  1.4 10.1 5.3 
Undifferentiated  
 
 
NRǂ 1.00  0.9 4.3 0 6.84 0.0631  1.7 17.7 5.9 3.99 0.1801  1.2 0 0 11.09 0.0240  1.2 9.4 3.6 
No histological 
evidence 
 
5.2 38.1 33.3 1.00  0.6 6.9 0 2.53 <.0001  0.8 16.3 12.2 1.94 0.0015  0.5 11.6 6.8 2.12 0.0002  0.5 10.9 6.9 
Total 13.9 52.4 38.2 1.00  0.9 6.7 2.8 3.93 <.0001  1.6 16.6 9.3 2.66 <.0001  0.8 11.4 6.0 3.36 <.0001  0.8 13.2 7.4 
ǂNR = Not reported in accordance with the cd-link DUA 
OS  = Median overall survival in months  
CUP with metastatic sites localized to lymph nodes (ICD-9:196/ICD-10:C77) used as the reference group in HR calculations 
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Figures 
 
 
Figure 1: Cohort identification flowchart. 
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Figure 2: Kaplan-Meier survival curves for CUP patients with a valid histology or missing histology. CUP, 
cancer of unknown primary. 
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Figure 3: Kaplan-Meier survival curves for patients with CUP coded as 196, 197, 198 or 199. CUP, cancer 
of unknown primary. 
 
  
18 
 
Figure 4: Kaplan-Meier survival curves of CUP patients with (A) adenocarcinoma, (B) squamous cell 
carcinoma, (C) unspecified carcinoma, or (D) undifferentiated histology. CUP, cancer of unknown 
primary. 
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